Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

90 results about "S100A8" patented technology

S100 calcium-binding protein A8 (S100A8) is a protein that in humans is encoded by the S100A8 gene. It is also known as calgranulin A. The proteins S100A8 and S100A9 form a heterodimer called calprotectin.

Reducing cutaneous scar formation and treating skin conditions

InactiveUS20150065431A1Reducing cutaneous scar formationBiocideTetrapeptide ingredientsS100A9Wound dressing
The present invention provides methods of reducing cutaneous scar formation by treating a cutaneous wound with a composition comprising a therapeutic agent that is a sodium channel blocker and / or an inhibitor of the Nax / SCN7A pathway. The present invention also provides wound cover components impregnated with such compositions, kits composed of such compositions with a wound dressing or sterile wipe, and mixtures of such compositions with a topical component (e.g., cream, ointment, or gel) suitable for application to a cutaneous wound. The present invention also provides compositions, kits, devices, and methods for treating skin conditions (e.g., dermatitis, psoriasis, or other skin conditions) with such compositions and devices. Examples of such therapeutic agents include, but are not limited to, an inhibitor of a gene or protein selected from: ENac, COX-2, PGE2, PI3K, PKB, Nax Prss8, IL-1β, IL-8, SAPK, Erk gene, p38 gene, PAR2, S100A8, S100A9, S100A12.
Owner:NORTHWESTERN UNIV

S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment

The present invention relates to a method and composition for inducing lymphocyte proliferation and migration, and for reducing the risks of microbial infections in patients immuno-supressed. The present invention particularly relates to the use of S100 protein, such as MRP, to induce the proliferation, differentiation and release of immune cells from bone marrow. More particularly, S100A8, S100A9, S100A12 and S100A8 / A9 are administered to patients with lowered neutrophil blood concentrations.
Owner:UNIV LAVAL

Methods for diagnosing and treating cancer

Aspects of the present invention relate to molecular biology and medicine. More specifically, some embodiments include methods for treating and / or diagnosing inflammation and / or cancer using agents that inhibit the binding of a pro-inflammatory protein or protein complex (e.g., S100A8 and / or S100A9) to a carboxylated glycan expressed on a myeloid (e.g., MDSC), monocytic, dendritic, endothelial, or tumor cell.
Owner:BURNHAM INST FOR MEDICAL RES +1

Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood

It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue.
Owner:STEMRIM INC +1

Immunomodulatory agents for treatment of inflammatory diseases

The present invention provides methods and compositions suitable for treating inflammatory disorders such as allergy, asthma, artherosclerosis, autoimmune disease, infection, injury, meningitis, psoriasis, and transplant rejection. In particular, the present invention provides methods and compositions comprising human S100A8 and / or S100A9 for reducing inflammation.
Owner:RGT UNIV OF CALIFORNIA

Pharmaceutical Agent for Promoting the Functional Regeneration of Damaged Tissue

The present inventors assessed the possibility that bone marrow-derived cells are mobilized to the grafted skin from nonskin tissues and contribute to skin tissue regeneration during the engraftment of grafted skin on biological tissues. As a result, the present inventors for the first time in the world demonstrated that:(1) a large number of bone marrow-derived cells are mobilized to grafted skin;(2) mobilized bone marrow-derived cells differentiate into any of dermal fibroblasts, adipocytes, muscle cells, vascular endothelial cells, and epidermal keratinocytes in grafted skin, and thus mobilized bone marrow-derived cells include bone marrow-derived mesenchymal stem cells;(3) S100A8 and S100A9 released from necrotic tissues of grafted skin are responsible for mobilizing bone marrow-derived mesenchymal stem cells to the grafted skin from peripheral blood; and(4) purified S100A8 and S100A9 promote the migration of mesenchymal stem cells isolated / cultured from the bone marrow.
Owner:OSAKA UNIV +1

Antibodies against S100A8 and S100A9 proteins for modulating inflammatory reactions

InactiveUS7553488B2Reduce manifestation and reactionPeptide/protein ingredientsAntipyreticNucleotideFactor ii
The present invention relates to compounds and methods for modulating, reducing or inhibiting, inflammatory reactions in a patient. Particularly, inflammatory reactions that are targeted by the present invention are cell migration, secretion of toxic products and proteolysis at a site of inflammation. Reduction of inflammation manifestations and reactions occurs by using an anti-S100 polynucleotide or polypeptide inhibitor or antagonist, which is essentially targeted against S100A8, S100A9 or S100A12, alone or in combination with other inhibitors of chemokines or immune modulating products.
Owner:UNIV LAVAL

Method for early monitoring radioactive pneumonia fibrosis caused by tumor radiotherapy

The invention relates to a method for early monitoring radioactive pneumonia fibrosis caused by tumor radiotherapy, in particular to a method for early diagnosis and prognosis evaluation of radioactive pneumonia by using a molecular marker. By the design of primers S100A8 and S100A9 and antibodies of a human, generation of the radioactive pneumonia and the pulmonary fibrosis can be monitored in the early stage, and the prognosis of diseases can be estimated. The method has the advantages of simple operation, high sensitivity and high specificity.
Owner:QINGDAO CENT HOSPITAL

Method for taking molecular marker in diagnosis and prognosis evaluation of breast cancer

The invention relates to a method for taking the breast cancer molecular marker S100A8 / A9 in diagnosis and prognosis evaluation of the breast cancer. According to the method, results show that the expression indexes of the molecular marker S100A8 / A9 in breast cancer patients with different molecular pathological subtypes are different, that is, thesubtypemolecular marker S100A8 / A9 is highly expressed in a substrate cellular type (basal-like) breast cancer patient and a Her-2 amplified) overexpression type breast cancer patient, but is relatively low in expression index in a lumen epithelia A type (Luminal A) breast cancer patient and a lumen epithelia B type (Luminal B) subtype breast cancer patient, that is, the statistic difference is obvious. For published NKI breast cancer chip data, patients are divided into a high group and a low group based on S100A8 / A9 for Kaplan-Meier survivorship curve analysis, results show that the negative correlation between the S100A9 expression level and the total survival rate is obvious, the prognosis of a breast cancer patient with high S100A9 expression is poor, and the prognosis application value of prompting breast cancer is high.
Owner:JIAXING CITY NO 2 HOSPITAL

BIOMARKERS FOR IgA NEPHROPATHY AND APPLICATIONS THEREOF

InactiveUS20110183349A1Microbiological testing/measurementDisease diagnosisSecreted Phosphoprotein 1Butyrophilin
The present invention provides a method for diagnosis or prognosis of IgA nephropathy in a subject based on detection of the expression level of one or more biomarker genes selected from the group consisting of thymosin β4 (Tmsb4), serine or cysteine proteinase inhibitor clade E member 2 (Serpine2), secreted phosphoprotein 1 (OPN), butyrophilin-like-2 (BTNL2), S100 calcium binding protein A8 (S100A8), Cystatin C (CysC), and any combination thereof.
Owner:NAT DEFENSE MEDICAL CENT

S100 protein family-based acute pancreatitis severity prediction model and detection method thereof

The invention discloses an S100 family-based acute pancreatitis severity prediction model and detection method thereof, and belongs to the technical field of acute pancreatitis detection. The acute pancreatitis severity prediction model is established by utilizing S100A6, S100A8, S100S9, S100A11, S100A12 and S100P in the S100 protein family; and for severe acute pancreatitis, the prediction modelhas a diagnosis sensitivity of 92.30%, a specificity of 84.70%, a false positive rate of 15.30% and a false negative rate of 7.70%. Compared with the present clinically used scale detection and imaging diagnosis, the prediction model has reduced subjectivity, is more correct and has a quantitative detection effect.
Owner:FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV

Methods and Compounds for Preventing, Treating and Diagnosing an Inflammatory Condition

Provided is an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 63-79 or 73-85 of the human protein S100A9. Provided is further an antibody with a specificity to an epitope that is a region corresponding to amino acid positions 55-71 of the human protein S100A8. Provided is further the use of such antibody in the treatment or diagnosis of an inflammatory disorder. Also provided is an in-vitro method of identifying a compound capable of inhibiting the formation of a complex between a peptide corresponding to one of the above epitopes of S100A9 or the above epitope of S100A8 and a TLR4 receptor, where a compound suspected to affect the complex formation is contacted with the peptide and the TLR4 receptor. Further provided is an in-vitro method of identifying a compound capable of increasing the stability of a complex between a S100A8 protein and a S100A9 protein, where the two proteins are contacted in the presence of a compound suspected to affect the complex formation.
Owner:WESTFAELISCHE WILHELMS UNIV MUENSTER

Molecular signature representative of dysfunctions in epidermal homeostasis

InactiveUS20100055694A1Preventing water lossMicrobiological testing/measurementS100A9GPX3
The present invention concerns a method for evaluating the epidermal homeostasis of the skin of a subject, comprising differential analysis of the expression of a gene, preferably of two genes, selected from the group of genes consisting of KRT6B, KRT16, ESRRA, CBX3, MAP3K5, TRIO, PIK3CD, TCRB, PRRG2, ICP22BP, GPX3, GBA, BPGM, NID1, SMT3H2, LGALS2, DOC1, PRKCG, S100A8, S100A9, S100A2, S100A7, K15, SPRR1B and GSN in response to a physical or chemical challenge of the stratum corneum. It also concerns various methods for diagnosing the state of the epidermis of an individual and methods for detecting and screening products or procedures which can improve epidermal homeostasis. The invention also pertains to kits and arrays which can be used in these various methods and processes.
Owner:ROLLS ROYCE PLC +1

Method for treating microbial infections

A method for treating a microbial infection or an abscessed tissue in a subject includes administering to the subject an effective amount of a metal ion chelator. In some embodiments, the metal ion chelator can be a protein, such as a calprotectin heterodimer. In some embodiments, the metal ion chelator is a calprotectin heterodimer including an S100A8 polypeptide and an S100A9 polypeptide.
Owner:VANDERBILT UNIV

siRNA for inhibiting gene expression of s100a8 and application thereof

The invention discloses a siRNA for inhibiting gene expression of S100A8 and an application thereof and relates to the field of molecular biology. The sequences of the siRNA for inhibiting gene expression of S100A8 are as follows: the positive-sense strand: 5'-CCAGGAGUUCCUCAUUCUG-3'; the antisense strand: 5'-CAGAAUGAGGAACUCCUGG-3'. The siRNA disclosed by the invention can be used for reducing expression of the gene S100A8 and inhibiting expression of gene MMP7 in a nasopharyngeal carcinoma cell CNE1, so that the migration function of the nasopharyngeal carcinoma cell is weakened. Therefore, the siRNA can be applied to researching drugs for treating nasopharynx cancer.
Owner:GUANGXI MEDICAL UNIVERSITY

Methods of diagnosing, monitoring treatment and treating systemic lupus erythematosus (SLE)

A method of treating systemic lupus erythematosus (SLE) in a subject are provided. The method comprise altering in cells of the subject activity and / or expression of at least one gene selected from the group consisting of Mpo, Ltf, Lcn, Camp, Ngp, Slfn, Ctsg, Thbs1, S100a8, 1190003K14Rik, Prtn3, S100a9, Tfpi, Fzd6, Nid1, 5830484A20Rik, 5830484A20 LOC 545340, Tnfsf4, IPstpip2, Pigr, 270022B06Rik, L5R-alpha, A130040M12Rik, Gpr132, Cd8b1, Dhx9, Cyp11a1, Lmo7, Rnf184, Pstpip2, Hdgfrp3, Ass1 and Zbtb20, thereby treating SLE. Also provided are methods of diagnosing SLE and monitoring treatment of SLE.
Owner:YEDA RES & DEV CO LTD

Chemiluminiscence quantitative detection for excrement calprotectin, and detection method and application thereof in intestinal health detection

The invention discloses chemiluminiscence quantitative detection for excrement calprotectin, a detection method thereof and an application thereof in intestinal health detection. The chemiluminiscencequantitative detection adopts a detection reagent, and comprises an immune complex and an antibody detection system, wherein the immune complex comprises a calprotectin calibrator, a calprotectin control product, and a labeled calprotectin complex antibody formed by compounding a labeled first specific antibody, a labeled second specific antibody and a to-be-detected sample. The combination modeof the first specific antibody, the second specific antibody and calprotectin is as follows: one antibody is specifically combined with an amino acid epitope in an amino acid sequence of a calprotectin S100A8 peptide chain, and the other antibody is specifically combined with an amino acid epitope in an amino acid sequence of a calprotectin S100A9 peptide chain. The chemiluminiscence quantitativedetection for excrement calprotectin, the detection method thereof and the application thereof can precisely and quantitatively detect the content of calprotectin in a human excrement sample, have theadvantages of high sensitivity and good stability, and have high clinical auxiliary value for intestinal health detection.
Owner:EPITOPE BIOTECH

Methods and kits for the rapid determination of patients at high risk of death during severe sepsis and septic shock

The present invention provides for the in vitro establishing of a prognosis for a subject in severe sepsis with at least two organ failures or in septic shock with at least two organ failures. Embodiments of the invention comprise the steps of measuring the level of the S100A8 / A9 complex from a biological sample from a subject, and comparing the measured level to a predetermined threshold in which the measured level of the S100A8 / A9 complex above the predetermined threshold is indicative of a bad prognosis and a measured level of the S100A8 / A9 complex below the predetermined threshold is indicative of a good prognosis.
Owner:ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

Plasma protein marker, detection reagent or detection tool for diagnosing severe-to-critical symptom of new coronal virus pneumonia

The invention relates to the technical field of biology, in particular to a plasma protein marker, a detection reagent or a detection tool for diagnosing severe-to-critical symptomsof the new coronalpneumonia. ELISA detection finds that concentrations of cholesterol ester transfer protein, calcium binding protein S100A8, calcium binding protein S100A9 and C reactive protein have significant differences in plasma of a severe patient and a critical patient, so that the accuracy of the OBC combination for predicting severe cases to critical cases is further determined.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI

Methods for diagnosing and treating schizophrenia

The genes encoding SCYA2, GADD45B, S100A8, CDKN1A, IL1RL1, TGM2, MAFF, SERPINA3, GRO1, CD14, KIAA1075, CHI3L1, SERPINH1, MT1X, KIAA0620, TIMP1, NUMA1, DDIT3 and TOB2, are upregulated in the anterior cingulate of schizophrenic patients compared to normal patients and as such are useful drug targets for schizophrenia. Methods of screening, diagnosing and treating schizophrenia based on these genes are provided. Transgenic nonhuman animals having increased copy number or increased expression levels of these genes are also provided. The transgenic nonhuman animals are used in methods for screening for potential therapeutic agents.
Owner:NOVARTIS AG +1

Immunohistochemical diagnosis kit for colorectal cancer malignancy and metastasis of colorectal cancer

The invention discloses an immunohistochemical diagnosis kit for colorectal cancer malignancy and metastasis of colorectal cancer. The kit comprises an endogenous peroxidase inhibitor, a non-specific binding site inhibitor, a primary antibody, a secondary antibody, an enzyme and a color developing agent. The immunohistochemical diagnosis kit is characterized in that the primary antibody is a human S100A8 monoclonal antibody or a murine S100A8 monoclonal antibody, and the secondary antibody is biotin-labeled goat anti-mouse IgG or rabbit anti-mouse IgG. According to the kit, expressions of S100A8 antigens on the surface of colorectal pathological tissues are detected, so that the colorectal cancer malignancy and metastasis conditions can be rapidly and accurately judged, and a help is provided for clinical diagnosis of the colorectal cancer.
Owner:CENT SOUTH UNIV

Methods and Kits for the Rapid Determination of Patients at High Risk of Death During Severe Sepsis and Septic Shock

The present invention provides methods and kits to obtain an early evaluation of mortality risk and help therapeutic decisions for patients in severe sepsis with two organ failures, for example for patients in septic shock. The invention is based on the measure of the level of S100A8 / A9 complex in plasma, since a level of S100A8 / A9 above a predetermined threshold is indicative of a bad prognosis and a level of S100A8 / A9 below said predetermined threshold is indicative of a good prognosis.
Owner:ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

Compounds and methods for the detection of calprotectin

PendingUS20180017576A1Accurate detectionRisk of relapse during remissionDisease diagnosisBiological testingCalprotectinS100A9
The present invention relates to a compound for use in a method of diagnosing acute or chronic inflammatory diseases in a subject. In particular, the present invention provides a S100A8 / S100A9 heterodimer standard comprising at least one mutation in low- or high-affinity calcium binding hand that can be used in a method of detecting biomarkers of inflammation in a sample. Accordingly, the S100A8 / S100A9 heterodimer standard allows for standardizing quantitative immunoassays and quantifying S100A8 / S100A9 heterodimers.
Owner:WESTFALISCHE WILHELMS UNIV MUNSTER

METHOD FOR GENERATION OF REGULATORY T-CELLS USING FACTORS SECRETED BY iNKT CELLS

The current invention concerns the use of PIP or S100A8 for the generation of regulatory T cells. The current invention provides a method of generating regulatory T cells by contacting immature DC with PIP or S100A8 to produce tolerogenic DC and further contacting naïve T cells to the tolerogenic DC to produce regulatory T cells. The invention also concerns PIP protein where immature DC contacted with PIP produce tolerogenic DC that induce conversion of naïve T-cells into regulatory T cells. The invention also concerns S100A8 protein where immature DC contacted with S100A8 produce tolerogenic DC that induce conversion of naïve T-cells into regulatory T cells. The invention also provides methods for identification of factors secreted by iNKT cells that induce conversion of immature DC into tolerogenic DC. The subject invention also concerns using regulatory T cells for treatment and / or management of cancer or the diseases of the immune system.
Owner:UNIV OF FLORIDA RES FOUNDATION INC

Diagnosis of mild or severe periodontitis

PendingCN111954818ASimple and Straightforward Diagnostic TestTransferasesLaboratory glasswaresSaliva sampleCalcium-binding protein
Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of three bio marker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Pyruvate Kinase (PK) and at least twoof Haemoglobin-beta (Hb-beta), Haemoglobin-delta (Hb-delta), S100 calcium-binding protein A8 (S100A8) and S100 calcium-binding protein A9 (S100A9). Based on the concentrations as measured, a value reflecting the joint concentrations for said proteins is determined. The value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in the patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for mild periodontitis in the patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for advanced periodontitis in the patient.
Owner:KONINKLJIJKE PHILIPS NV

Application of serum S100a8/9 complex level in diagnosis and prognosis of acute myocardial infarction

The invention relates to application of serum S100a8 / 9 complex level in diagnosis and prognosis of acute myocardial infarction. The prognosis is characterized by predicting conditions of prognosis ofAMI patients after percutanecus coronary intervention and distinguishing the patients into a group with high risk of postoperative adverse events and a group with low risk of postoperative adverse events; the adverse events comprise and are not limited to death and acute heart failure.
Owner:BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products